Last reviewed · How we verify
ERIVEDGE
Erivedge (vismodegib) inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation.
Erivedge (vismodegib) inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation. Used for Locally advanced basal cell carcinoma, Metastatic basal cell carcinoma.
At a glance
| Generic name | ERIVEDGE |
|---|---|
| Also known as | VISMODEGIB |
| Sponsor | University Hospital, Lille |
| Drug class | Hedgehog pathway inhibitor |
| Target | Smoothened (SMO) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Vismodegib is a small-molecule inhibitor that binds to and blocks Smoothened (SMO), a G-protein coupled receptor essential for Hedgehog pathway signaling. The Hedgehog pathway is aberrantly activated in basal cell carcinoma and other cancers, driving uncontrolled cell proliferation. By inhibiting this pathway, vismodegib suppresses tumor cell growth and survival.
Approved indications
- Locally advanced basal cell carcinoma
- Metastatic basal cell carcinoma
Common side effects
- Muscle cramps
- Alopecia
- Dysgeusia (taste disturbance)
- Weight loss
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Vismodegib in Treating Patients With Advanced Chondrosarcomas (PHASE2)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (PHASE1)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas (PHASE2)
- Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (PHASE1)
- Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma (EARLY_PHASE1)
- Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERIVEDGE CI brief — competitive landscape report
- ERIVEDGE updates RSS · CI watch RSS
- University Hospital, Lille portfolio CI